Testing requirements have surged and that has meant that companies such as Metropolis Healthcare Ltd have got an opportunity to grow exponentially. Shares of Metropolis have more than doubled in the past year, outperforming larger peer Dr Lal PathLabs Ltd. While the Metropolis stock has gained 109%, Dr Lal stock rose 96%. Metropolis currently provides home collection in 65 cities, which it plans to increase to 100 cities by this year-end, doubling it by next year. Notably, revenues per patient were much better than the roughly ₹733 clocked by Dr Lal PathLabs.

Source: Mint July 08, 2021 16:52 UTC